91
Participants
Start Date
April 12, 2021
Primary Completion Date
July 4, 2023
Study Completion Date
July 4, 2023
BRII-835 (VIR-2218)
BRII-835 (VIR-2218) will be given by subcutaneous injection
BRII-179 (VBI-2601) with IFN-α
BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
BRII-179 (VBI-2601)
BRII-179 (VBI-2601) will be administered by intramuscular injection
Investigative Site 88602, Changhua, Taiwan
Investigative Site 64001, Auckland
Investigative Site 61001, Westmead
Investigative Site 61002, Kingswood
Investigative Site 82001, Seoul
Investigative Site 82005, Seoul
Investigative Site 61004, Herston
Investigative Site 82002, Seoul
Investigative Site 64002, Dunedin Central
Investigative Site 88605, Taipei CITY
Investigative Site 66001, Bangkok
Investigative Site 66005, Nonthaburi
Investigative Site 66006, Nonthaburi
Investigative Site 66004, Pathum Thani
Investigative Site 82003, Seongnam-si, Gyeonggi-do
Investigative Site 66002, Khon Kaen
Investigative Site 88603, Taichung, Taiwan
Investigative Site 82004, Busan
Investigative Site 66003, Chiang Mai
Investigative Site 88601, Kaohsiung, Taiwan
Investigative Site 66007, Songkhla
Investigative Site 65001, Singapore
Investigative Site 65002, Singapore
Investigative Site 85201, Hong Kong
Investigative Site 85202, Hong Kong
Investigative Site 85203, Hong Kong
Investigative Site 88604, Kaohsiung, Taiwan
Investigative Site 85204, NEW Territories, Hong Kong
Lead Sponsor
Vir Biotechnology, Inc.
INDUSTRY
VBI Vaccines Inc.
INDUSTRY
Brii Biosciences Limited
INDUSTRY